A Multi-Site, Open-Label, Partially-Randomized Trial of the Efficacy and Safety of Fixed Dose Elbasvir/Grazoprevir (EBR/GZR) Based Regimens in French Subjects With Chronic Hepatitis C Virus (HCV) Genotype 4 Infection
Phase of Trial: Phase IV
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 15 Aug 2017 Planned End Date changed from 8 Oct 2018 to 6 Oct 2018.
- 15 Aug 2017 Planned primary completion date changed from 8 Oct 2018 to 6 Oct 2018.
- 07 Jul 2017 Status changed from not yet recruiting to recruiting.